ruxolitinib
novartis,incyte,orion corp
['ruxolitinib', 'rux,(-crux),(-trux),(-deruxtecan)', 'orion ']
congress #ash22 | franco locatelli presents data from reach4, a phase i/ii study of ruxolitinib in pediatric pts with grade ii-iv treatment na ve or sr-agvhd. n = 45. orr in all patients was 84.4% at day 28, with a durable orr at day 56 of 66.7% #gvhd #bmtsm 
A global online platform providing latest treatment options and medical information in graft-versus-host disease (GvHD). #gvhd